Uptake of a Switching Program for Patients Receiving Intravenous Infliximab and Vedolizumab to Subcutaneous Preparations

被引:14
作者
Burdge, Gemma [1 ]
Hardman, Alice [1 ]
Carbery, Isabel [1 ]
Broglio, Giacomo [1 ,2 ]
Greer, Dan [1 ]
Selinger, Christian P. [1 ,3 ]
机构
[1] Leeds Teaching Hosp NHS Trust, Gastroenterol, Leeds LS7 4SA, W Yorkshire, England
[2] IRCCS Fdn Policlin San Matteo, Internal Med, I-27100 Pavia, Italy
[3] Univ Leeds, Res Inst, St James Hosp, Leeds LS9 7TF, W Yorkshire, England
关键词
inflammatory bowel disease; infliximab; vedolizumab; INFLAMMATORY-BOWEL-DISEASE; MAINTENANCE THERAPY; CROHNS-DISEASE; INDUCTION;
D O I
10.3390/jcm11195669
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Recent trials support the clinical efficacy and safety of subcutaneous infliximab (IFX) or vedolizumab (VDZ) for Inflammatory Bowel Disease (IBD). We evaluated the uptake and rationale for choosing to switch from intravenous infusions to subcutaneous injections. Methods: Retrospective analysis of all adult patients receiving standard dosing IFX or VDZ maintenance therapy to investigate uptake of subcutaneous injections and the rationale for switching to subcutaneous injections. Results: Of 232 eligible patients (total = 258: IFX = 190, VDZ = 68, and no longer eligible = 26), 58% of patients on IFX and 59% of patients on VDZ chose to switch to subcutaneous treatment. Age, sex, diagnosis, drug, line of treatment, and duration of treatment were not predictors for willingness to switch. Questionnaire responses (n = 51) demonstrate that the decision to switch was not influenced by COVID-19 exposure risk, impact on wider IBD service provision, impact on patient mental health, financial savings, seeking support following a switch, or a sense of independence managing IBD. Switchers (68%) were more motivated by time savings than non-switchers (25%; p = 0.0042). Conclusions: Switch uptake rates were 58%, with 90% of patients eligible to switch. Switch decision was influenced by time savings for patients but not by other patient-related factors.
引用
收藏
页数:7
相关论文
共 14 条
[11]   Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease [J].
Sandborn, William J. ;
Feagan, Brian G. ;
Rutgeerts, Paul ;
Hanauer, Stephen ;
Colombel, Jean-Frederic ;
Sands, Bruce E. ;
Lukas, Milan ;
Fedorak, Richard N. ;
Lee, Scott ;
Bressler, Brian ;
Fox, Irving ;
Rosario, Maria ;
Sankoh, Serap ;
Xu, Jing ;
Stephens, Kristin ;
Milch, Catherine ;
Parikh, Asit .
NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (08) :711-721
[12]   Randomized Controlled Trial: Subcutaneous vs Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease [J].
Schreiber, Stefan ;
Ben-Horin, Shomron ;
Leszczyszyn, Jaroslaw ;
Dudkowiak, Robert ;
Lahat, Adi ;
Gawdis-Wojnarska, Beata ;
Pukitis, Aldis ;
Horynski, Marek ;
Farkas, Katalin ;
Kierkus, Jaroslaw ;
Kowalski, Maciej ;
Lee, Sang Joon ;
Kim, Sung Hyun ;
Suh, Jee Hye ;
Kim, Mi Rim ;
Lee, Seul Gi ;
Ye, Byong Duk ;
Reinisch, Walter .
GASTROENTEROLOGY, 2021, 160 (07) :2340-2353
[13]   Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trial [J].
Van Assche, Gert ;
Vermeire, Severine ;
Ballet, Vera ;
Gabriels, Frederik ;
Noman, Maja ;
D'Haens, Geert ;
Claessens, Christophe ;
Humblet, Evelien ;
Casteele, Niels Vande ;
Gils, Ann ;
Rutgeerts, Paul .
GUT, 2012, 61 (02) :229-234
[14]  
Verma AM, 2021, LANCET GASTROENTEROL, V6, P88, DOI 10.1016/S2468-1253(20)30392-7